Related Experiment Videos
GTI-2501. Lorus Therapeutics
1Department of Pathology, Cell Biology and Anatomy, Thomas Jefferson University, Philadelphia, PA 19107, USA. Guang-Chou.Tu@mail.tju.edu
Abstract:
Lorus Therapeutics (formerly GeneSense Technologies) is developing GTI-2501, directed against the R1 component of ribonucleotide reductase, for the potential treatment of cancer [348928]. In November 2000, the company filed an IND with the FDA in preparation to begin a phase I trial in the US in the first quarter of 2001 [389975], [396537], [397960]. In March 2001, the FDA approved the IND application [402350], and in June 2001, a phase I, dose-escalating trial in patients with lymphomas or solid tumors which have not responded to standard therapy commenced in the US [412225]. The company expected the phase I trial of GTI-2501 to be completed within 12 to 15 months [420582]. In November 1999, the company reported that in preclinical trials, GTI-2501 was an effective anticancer agent when tested in standard mouse models bearing a variety of different human cancer lines including tumor cells derived from lung, breast, colon, kidney, ovary pancreas and skin cancers [348928]. Lorus received a patent from the US PTO in January 2000, covering the design and use of unique anitisense anticancer drugs, including GTI-2501 and GTI-2040 [353538]. In June 2000, the USPTO allowed a patent to specifically protect GTI-2501 [370810].
Insights
GTI-2501, an anticancer drug targeting ribonucleotide reductase, showed effectiveness in preclinical cancer models. A Phase I trial is underway to evaluate its safety and efficacy in patients with refractory lymphomas and solid tumors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lorus Therapeutics is developing GTI-2501, an antisense anticancer drug.
- GTI-2501 targets the R1 component of ribonucleotide reductase.
Purpose of the Study:
- To evaluate the safety and efficacy of GTI-2501 in cancer patients.
Main Methods:
- A Phase I, dose-escalating clinical trial was initiated in the US.
- The trial enrolled patients with refractory lymphomas or solid tumors.
Main Results:
- Preclinical studies demonstrated GTI-2501's efficacy in various human cancer models.
- The drug showed effectiveness against lung, breast, colon, kidney, ovary, pancreas, and skin cancer cell lines.
Conclusions:
- GTI-2501 holds potential as an anticancer therapeutic.
- Further clinical evaluation is warranted based on preclinical data.